Paul Wotton, Ph.D., 64 Independent Chairman and Managing Partner, RBL, LLC; Adjunct Professor, Rice University Director Since: 2015 Other Current Public Company Directorships: Vericel Board committee(s): Cynata Therapeutics Limited Compensation and Governance and Nominating Committees Key Experience and Qualifications BioPharma/Complex Biologics/ Business Development/Marketing and Sales: Dr. Wotton has served in key leadership roles across the pharmaceutical and biotech industries throughout his career and has been integral in a number of high-profile business development transactions during that period. While CEO of Obsidian Therapeutics, Inc., Dr. Wotton spearheaded key deals with Vertex Pharmaceuticals and M.D. Anderson, and earlier in his career, while CEO at Siglion Therapeutics, Inc., he implemented the agreement that resulted in the eventual acquisition of the company by Eli Lilly and Company. Dr. Wotton s experiences provide key insight to the Vericel leadership team as the Company continues to investigate expanding its product portfolio with another highly-synergistic therapy. Professional Highlights President and Chief Executive Officer and a board member of Obsidian Therapeutics, Inc., a privately-held company (2019-2022) Founding President and Chief Executive Officer of Sigilon Therapeutics, Inc., a cell therapeutics company (2016-2019) President and Chief Executive Officer and member of the board of directors of Ocata Therapeutics, Inc. (from July 2014 until its acquisition by Astellas Pharma US, Inc. in February 2016) President and Chief Executive Officer and member of the board of directors of Antares Pharma, Inc., a publicly-traded biopharmaceutical company (2008-2014) Held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme Other Leadership Positions and Experiences Chair of the board of directors of Kytopen, a privately-held biotechnology company focused on developing cellular and genome engineering platforms Former member of the board of directors and Chairman of the compensation committee of Veloxis Pharmaceuticals A/S Past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada Named Ernst & Young Entrepreneur of the Year for Life Sciences, New Jersey, in 2014 Education Bachelor s in Pharmacy, with honors, from University College London Ph.D. in pharmaceutical sciences from the University of Nottingham M.B.A. from Kingston Business School